Search
Xylitol
go.drugbank.com/drugs/DB11195ApprovedInvestigationalXylitol is a non-fermentable sugar alcohol by most plaque bacteria, indicating that it cannot be fermented into cariogenic acid end-products [A32423]. … The recommended dose of xylitol for dental caries prevention is 6–10 g/day, and most adults can tolerate 40 g/day without adverse events [A22081].
Mixtures: Fluor-a-day, Fluor-a-dayCategories: Compounds used in a research, industrial, or household settingFebuxostat
go.drugbank.com/drugs/DB04854ApprovedInvestigationalGout is closely associated with hyperuricemia. Febuxostat works by inhibiting the activity of an enzyme that is responsible for the synthesis of uric acid, thereby reducing serum uric acid levels. … [L32238] Gout is a form of arthritis that is caused by the accumulation of uric acid crystal in or around a joint, leading to inflammation and further deposition of uric acid crystal deposition in bones
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSynonyms: 2-(3-cyano-4-isobutoxyphenyl)-4-methyl- 1,3-thiazole-5-carboxylic acidTechnetium Tc-99m oxidronate
go.drugbank.com/drugs/DB09139ApprovedWithdrawn[L1138] These complexes are formed by the binding of 99mTc to metal atoms of an organic molecule. … [L1140] It was developed by Mallinkrodt nuclear and FDA approved on February 18, 1981.
Glucarpidase
go.drugbank.com/drugs/DB08898ApprovedInvestigational[A244750] Glucarpidase is an enzyme that can rapidly hydrolyze methotrexate into its nontoxic metabolites. … [L39855] Glucarpidase was first approved by the FDA in January 2012,[A7476] followed by the European Commission's approval in January 2022.[L39865] It is marketed as VORAXAZE.
Palivizumab
go.drugbank.com/drugs/DB00110ApprovedInvestigationalHumanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). … Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF)
Categories: Respiratory Syncytial Virus Anti-F Protein Monoclonal AntibodyProducts: SYNAGIS 100 MG/1 ML IM ENJEKSIYONLUK ÇÖZELTI IÇEREN FLAKON,1 ADET, SYNAGIS 100 MG/1 ML IM ENJEKSIYONLUK ÇÖZELTI IÇEREN FLAKON, 1 ADETJanssen COVID-19 Vaccine
go.drugbank.com/drugs/DB15857ApprovedInvestigationalThe Janssen COVID-19 vaccine is available under an Emergency Use Authorization (EUA) in the US.[L41745] … As of June 2020, a Phase 1/2 clinical trial in adult humans was announced to evaluate the safety, immunogenicity, and efficacy of the ad26.COV.S vaccine in 1045 healthy adults between the ages of 18-55
Synonyms: Ad26.COV2.S, AD26.COV2.S [RECOMBINANT]Cytochrome c oxidase subunit FA4
go.drugbank.com/bio_entities/BE0000169TargetHumansComponent of the cytochrome c oxidase, the last enzyme in the mitochondrial electron transport chain which drives oxidative phosphorylation. The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII...
Synonyms: Complex I-MLRQParathyroid hormone/parathyroid hormone-related peptide receptor
go.drugbank.com/bio_entities/BE0003508TargetHumansG protein-coupled receptor for parathyroid hormone (PTH) and for parathyroid hormone-related peptide (PTHLH) (PubMed:10913300, PubMed:11773434, PubMed:18375760, PubMed:19674967, PubMed:27160269, PubMed:30975883, PubMed:35932760, PubMed:8...
Synonyms: PTH/PTHrP type I receptorChymopapain
go.drugbank.com/drugs/DB06752ApprovedWithdrawn[L2482]It is an extracellular plant cysteine proteinase similar to papain in specificity.[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982. … Chymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest.
Products: Chymodiactin Injection - 4 Nkat Units/2mlUpadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigationalIt is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. … [A189165] Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies.
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors